Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 5312674, 5 pages
Research Article

Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome

1Department of Medical Genetics, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
2Department of Obstetrics and Gynecology, Aegean Maternity Teaching and Training Hospital, 35110 Izmir, Turkey
3Department of Obstetrics and Gynecology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
4Faculty of Medicine, Department of Medical Biology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey

Received 9 September 2015; Revised 24 December 2015; Accepted 7 February 2016

Academic Editor: Xia Li

Copyright © 2016 Biray Erturk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method. A total of 56 patients underwent invasive prenatal testing; 23 cases were carrying Down Syndrome affected fetuses, and 33 control cases carrying unaffected, normal karyotype fetuses were included for comparison. Indications for invasive prenatal testing were advanced maternal age, increased risk of Down Syndrome in screening tests, and abnormal finding in the sonographic examination. In both the study and control groups, all the pregnant women were at 17th and 18th week of gestation. miRNA expression levels were measured using real-time RT-PCR. Results. Significantly increased maternal plasma levels of miR-3156 and miR-99a were found in the women carrying a fetus with Down Syndrome. Conclusion. Our results provide a basis for multicenter studies with larger sample groups and microRNA profiles, particularly with the microRNAs which were found to be variably expressed in our study. Through this clinical research, the utility of microRNAs in noninvasive prenatal testing can be better explored in future studies.